Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer

Abstract

Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most chal-lenging breast cancer subtype to treat. This is largely related to the heterogeneity of this disease and the lack of reliable oncological targets. In this review, we discuss the current standard-of-care treatment options for metastatic TNBC, including recent advances with the use of immunotherapy, PARP inhibitors and antibody-drug conjugates. This review also explores new agents and novel combinations arising in the field for the treatment of advanced TNBC.